Table 2.
Comparison of baseline metabolic profile between P/I ratio responders and non-responders
| Responder | Non responder | |
|---|---|---|
| n (M/F) |
8 (5/3) |
7 (5/2) |
| BMI, kg/m2 |
23.6 ± 4.2 |
26.4 ± 4.1 |
| HbA1c(NGSP),% |
6.8 ± 0.4 |
6.9 ± 0.7 |
| HOMA-R |
1.85 ± 1.18 |
3.90 ± 4.58 |
| ISI (Matsuda’s index) |
9.30 ± 2.35 |
6.15 ± 3.23* |
| Insulinogenic index |
1.01 ± 0.69 |
0.43 ± 0.30* |
| PI/I ratio |
0.08 ± 0.06 |
0.13 ± 0.15 |
| CPR, nmol/L |
0.66 ± 0.33 |
0.66 ± 0.33 |
| (ng/dL) |
(2.0 ± 1.0) |
(2.0 ± 1.0) |
| Total cholesterol, mmol/L |
5.18 ± 1.21 |
5.54 ± 0.59 |
| (mg/dL) |
(200 ± 47) |
(214 ± 23) |
| Triglyceride, mmol/L |
1.19 ± 0.50 |
2.32 ± 1.40* |
| (mg/dL) |
(106 ± 45) |
(206 ± 124*) |
| HDL-C, mmol/L |
1.73 ± 0.51 |
1.16 ± 0.31* |
| (mg/dL) | (67 ± 20) | (45 ± 12*) |
Mean ± SD *P < 0.05 vs responder (paired t-test).
BMI, body mass index; HbA1c, hemoglobin A1c; NGSP, National Glycohemoglobin Standardization Program; HOMA-IR, homeostasis model assessment of insulin resistance; ISI, insulin sensitivity index; PI/I ratio, proinsulin/insulin ratio; CPR, C-peptide immunoreactivity; HDL-C, high-density lipoprotein cholesterol; IRI, immunoreactive insulin.